Reply to T.M. Weis et al

Nancy L. Bartlett; Wyndham H. Wilson; John P. Leonard

doi:10.1200/JCO.19.01617

Reply to T.M. Weis et al

Nancy L. Bartlett, Wyndham H. Wilson, John P. Leonard

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	2953
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	37
Issue number	31
DOIs	https://doi.org/10.1200/JCO.19.01617
State	Published - 2019

Access to Document

10.1200/JCO.19.01617

Cite this

@article{67dc70b231114a0cb1c2f2039d5c44bc,

title = "Reply to T.M. Weis et al",

author = "Bartlett, {Nancy L.} and Wilson, {Wyndham H.} and Leonard, {John P.}",

note = "Funding Information: John P. Leonard Consulting or Advisory Role: Celgene, Biotest, Sunesis Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Epizyme, Pfizer, Bayer, Genentech, ADC Therapeutics, MEI Pharma, AstraZeneca, Novartis, Merck, Sutter Medical Group, MorphoSys, BeiGene, Nordic Nanovector, Bristol-Myers Squibb, United Therapeutics, Karyopharm Therapeutics, Sandoz Research Funding: Celgene (Inst), Alliance for Clinical Trials in Oncology (Inst), Takeda (Inst), Pfizer (Inst), National Cancer Institute (Inst) Travel, Accommodations, Expenses: BeiGene",

year = "2019",

doi = "10.1200/JCO.19.01617",

language = "English",

volume = "37",

pages = "2953",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

number = "31",

}

TY - JOUR

T1 - Reply to T.M. Weis et al

AU - Bartlett, Nancy L.

AU - Wilson, Wyndham H.

AU - Leonard, John P.

N1 - Funding Information: John P. Leonard Consulting or Advisory Role: Celgene, Biotest, Sunesis Pharmaceuticals, Bristol-Myers Squibb, Gilead Sciences, Epizyme, Pfizer, Bayer, Genentech, ADC Therapeutics, MEI Pharma, AstraZeneca, Novartis, Merck, Sutter Medical Group, MorphoSys, BeiGene, Nordic Nanovector, Bristol-Myers Squibb, United Therapeutics, Karyopharm Therapeutics, Sandoz Research Funding: Celgene (Inst), Alliance for Clinical Trials in Oncology (Inst), Takeda (Inst), Pfizer (Inst), National Cancer Institute (Inst) Travel, Accommodations, Expenses: BeiGene

PY - 2019

Y1 - 2019

UR - http://www.scopus.com/inward/record.url?scp=85074308171&partnerID=8YFLogxK

U2 - 10.1200/JCO.19.01617

DO - 10.1200/JCO.19.01617

M3 - Letter

C2 - 31532721

AN - SCOPUS:85074308171

SN - 0732-183X

VL - 37

SP - 2953

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 31

ER -

Reply to T.M. Weis et al

Access to Document

Other files and links

Cite this